Browsing Category
Pharma Industry News
4718 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Insilico Medicine’s AI drug enters Phase III dosing. Can rentosertib clear the real test?
Insilico Medicine has dosed the first patient in its 320-patient Phase III GENESIS-IPF-3 study, moving rentosertib from an intriguing AI-drug discovery milestone into a year-long test of whether its earlier lung-function signal can survive pivotal clinical scrutiny.
Sernova (TSX: SVA) and Seraxis to merge as BetaNova targets 2027 diabetes trial
Sernova Biotherapeutics and Seraxis Holdings have agreed to combine into BetaNova Biotherapeutics, pairing Sernova’s Cell Pouch platform with stem cell-derived pancreatic islets, US$10 million of committed financing and a Phase 1/2 diabetes trial targeted to begin in early 2027.
Teva Pharmaceutical Industries moves to extend debt maturities as refinancing strategy accelerates
Teva Pharmaceutical Industries launches a new bond refinancing targeting costly 2027-2030 debt. Find out what it means for its $13 billion net debt.
Novartis India (NSE: NOVARTIND) pays Rs 1,250cr for Pfizer’s Minipress brands
Novartis India has acquired the Indian Minipress and Minipres trademarks and related intellectual property from Pfizer for approximately â‚ą1,250 crore, paying about 5.5 times the brand's reported annual sales as its new ownership begins reshaping the listed pharmaceutical company.
Avacta (AIM: AVCT) clears deferred bond repayments as AVA6103 milestones shape management options
Avacta has paid another ÂŁ2.61 million of its convertible bond in cash, reducing principal to ÂŁ12 million, days after granting management options equivalent to about 4.1% of current issued capital.
uniQure files AMT-130 in U.S. and U.K. as Huntington’s gene therapy reaches regulators
uniQure has submitted AMT-130 for accelerated U.S. approval and filed simultaneously in the United Kingdom, moving the Huntington’s gene therapy from regulatory planning into formal review.
GSK bets up to $1.3bn on HUTCHMED’s preclinical KRAS-EGFR cancer therapy
GSK will pay HUTCHMED $110 million upfront and up to $1.185 billion in additional milestones for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR conjugate expected to enter human trials later in 2026.
Novartis India buys Pfizer’s Minipress for Rs 1,250cr. Why is the price so large?
Novartis India has agreed to acquire Pfizer’s Minipress and Minipres trademarks and related Indian intellectual property for about ₹1,250 crore, making a transformative portfolio bet barely six weeks after Novartis AG exited control of the listed company.
Novartis and Ionis suffer pelacarsen setback as 8,000-patient heart trial misses endpoint
Novartis and Ionis Pharmaceuticals have suffered a major Phase III setback after pelacarsen successfully lowered lipoprotein(a) but failed to reduce cardiovascular events, challenging one of the most closely watched hypotheses in heart-drug development.
Clever Culture Systems (ASX: CC5) wins two more Novo Nordisk APAS orders
Clever Culture Systems Limited has received a purchase order from Novo Nordisk for two additional APAS Independence instruments and a custom laboratory-system integration, moving the pharmaceutical group from evaluation into formal global validation ahead of possible wider deployment.